The combination of pembrolizumab and chemotherapy enables patients with a PD-L1 tumor proportion score lower than 1%, a population with little chance of benefitting from single-drug PD-1 and PD-L1 inhibitors, to obtain survival benefits (12). This evidence concerns the gene CD274 and neoplasm.